After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.

Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.